Stocks · News reference

Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Aug 13, 2026, 2:16 PMBenzinga Newsdesk

Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 12, 2026, 2:11 PMBenzinga Newsdesk
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
Read original at benzinga
AVLN
BenzingaAug 12, 2026, 12:13 PMBenzinga Newsdesk
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
Read original at benzinga
AVLN
SEC EDGARAug 12, 2026, 12:06 PMSEC EDGAR
8-K filing — Avalyn Pharma Inc. (AVLN)
Filed: 2026-08-12 AccNo: 0001193125-26-345807 Size: 295 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
AVLN